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In South Korea, surveillance of antimicrobial drug resistance 
in Neisseria gonorrhoeae is extremely limited. We describe 
the emergence and subsequent national spread of N. gon-
orrhoeae strains with mosaic penA alleles associated with 
decreased susceptibility and resistance to extended-spec-
trum cephalosporins. From 2012 through 2017, the propor-
tion of mosaic penA alleles in gonococcal-positive nucleic 
acid amplification test (NAAT) specimens across South Ko-
rea increased from 1.1% to 23.9%. Gonococcal strains with 
mosaic penA alleles emerged in the international hubs of 
Seoul in Gyeonggi Province and Busan in South Gyeong-
sang Province and subsequently spread across South Ko-
rea. Most common was mosaic penA-10.001 (n = 572 iso-
lates; 94.7%), which is associated with cefixime resistance. 
We also identified mosaic penA-34.001 and penA-60.001, 
both of which are associated with multidrug-resistant gono-
coccal strains and spread of cefixime and ceftriaxone re-
sistance. Implementation of molecular resistance prediction 
from N. gonorrhoeae–positive nucleic acid amplification test 
specimens is imperative in South Korea and internationally.
Neisseria gonorrhoeae remains a major public health threat globally (1). During the past 2 decades, N. 
gonorrhoeae strains with resistance to extended-spectrum 
cephalosporins (ESCs), including ceftriaxone, the last re-
maining option for empiric first-line gonorrhea treatment, 
have emerged and spread internationally, which is a serious 
concern worldwide (2–23). Enhanced global antimicrobi-
al resistance (AMR) surveillance is crucial to controlling 
further spread of AMR strains. However, in many countries, 
culture-based AMR testing cannot be performed because 
most patients are treated empirically at primary-care facili-
ties or hospitals where culture is unavailable and nucleic 
acid amplification tests (NAATs) have replaced culture for 
diagnosis. Consequently, molecular methods for detection 
of AMR determinants in N. gonorrhoeae–positive NAAT 
specimens are essential (21).
For the currently recommended ESCs, resistance is 
influenced by many different mutations in various genes 
that collaboratively increase the MICs of ESCs (4,5,7,24). 
Nevertheless, the main mechanism for ESC resistance is 
the acquisition of a mosaic penA allele encoding a mosaic 
version of the ESC lethal target, penicillin-binding protein 
2 (24–32). Nearly all N. gonorrhoeae isolates with clinical 
or in vitro resistance to ESCs contain a mosaic penA allele. 
However, isolates with decreased susceptibility or suscep-
tibility to ESCs also can contain a mosaic penA allele; that 
is, different mosaic penA alleles can affect the ESC MICs 
differently (3–8,10–19,24–38). Accordingly, a molecular 
assay detecting all types of mosaic penA alleles can predict 
ESC resistance with a high sensitivity but lower specific-
ity (24–31). Currently, no molecular assays for detection of 
mosaic penA alleles and prediction of ESC resistance are 
commercially available.
In South Korea, ≈15,000 gonorrhea patients (≈29 
patients/100,000 population) are reported to the Korean 
Health Insurance System (http://opendata.hira.or.kr) an-
nually, but culture and AMR testing of N. gonorrhoeae 
are exceedingly limited (2,3). ESC resistance and ESC-
resistant N. gonorrhoeae strains with the mosaic penA-
10.001 allele were observed in 2011 in South Korea (3). 
Since the early 2000s, ESC-resistant N. gonorrhoeae 
strains containing the mosaic penA-10.001, associated 
with cefixime resistance, have been prevalent and caused 
cefixime treatment failures in Japan (4,5,7,33). In South 
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Cephalosporin-Resistant N. gonorrhoeae
Korea, molecular prediction of AMR directly from N. 
gonorrhoeae–positive NAAT samples is imperative for 
large-scale screening and prediction of the level and 
spread of ESC resistance in Korea.
We describe the emergence and subsequent national 
spread of N. gonorrhoeae strains with mosaic penA alleles 
in gonococcal-positive NAAT specimens across South 
Korea from 2012 through 2017. For molecular epidemi-
ology, penA sequencing, N. gonorrhoeae multiantigen 
sequence typing (NG-MAST), and multilocus sequence 
typing (MLST) were performed on all mosaic penA- 
positive specimens.
Materials and Methods
N. gonorrhoeae–Positive NAAT Specimens
We examined DNA extracts of NAAT specimens, main-
ly first-voided urine (55%) and vaginal swab specimens 
(27%), but also urethral and cervical swab specimens 
(18%), positive for N. gonorrhoeae (n = 3,884; 1 speci-
men per patient) by Seeplex NAATs (Seegene, http://
www.seegene.com). These DNA extracts were obtained 
from commercial centralized accredited laboratories 
(2012–2017, Seegene Medical Foundation and SamK-
wang Medical Laboratories; 2016–2017, U2Bio; and 
2017, Green Cross Medical Foundation) in Seoul, South 
Korea. The DNA extracts were stored at –70°C before 
further analysis. 
All samples were collected and preserved as part of the 
routine diagnostics, and no patient identification data were 
available during the study. Therefore, ethics approval was 
not required.
Detection of Mosaic penA Alleles
We examined all DNA extracts for mosaic penA alleles in 
2 steps: 1) screening of all types of mosaic penA alleles 
(7,34); and 2) detection of the specific mosaic penA al-
leles that caused high-level resistance to ceftriaxone in the 
strains H041 (penA-37.001; 7) and F89 (penA-42.001; 6). 
For screening of all types of mosaic penA alleles, we used a 
previously described TaqMan probe–based real-time PCR 
method on a Rotor-Gene 6000 (QIAGEN, https://www.
qiagen.com) (34). We then tested all DNA extracts positive 
for a mosaic penA allele by using a real-time PCR specific 
for penA-37.001 (35) and a modified hybridization probe-
based real-time PCR detecting penA-42.001 (36).
Sequencing of Mosaic penA Alleles
We sequenced the entire penA gene in all DNA specimens 
positive for a mosaic penA allele, as previously described 
(3,37). Among 604 mosaic penA-positive specimens, we 
were able to sequence 601 (99.5%) specimens. Three (0.5%) 
specimens failed to sequence due to low DNA content. The 
mosaic penA alleles were named by using the Neisseria 
gonorrhoeae Sequence Typing for Antimicrobial Resis-
tance (NG-STAR; 38) database (https://ngstar.canada.ca/ 
welcome/home).
Molecular Epidemiologic Characterization
We performed NG-MAST (39) and MLST on all mosaic 
penA-positive specimens using the methods described 
on the NG-MAST (http://www.ng-mast.net) and MLST 
(http://pubmlst.org/neisseria) websites. We successfully 
typed 594 (98.3%) of the mosaic penA-positive specimens 
with NG-MAST and 593 (98.2%) specimens with MLST. 
Antimicrobial Agents Used for Gonorrhea Treatment
We acquired prescription data for patients treated for gon-
orrhea from 2010 through 2017 in South Korea from the 
Korea Health Insurance Review & Assessment Service 
(http://opendata.hira.or.kr). In South Korea, all clinics and 
hospitals participate in the national health insurance sys-
tem, and reporting of prescription data and diagnosis to 
the Korea Health Insurance Review & Assessment Service 
HIRA is mandatory. We analyzed the percentage of diag-
nosed gonococcal infections in patients who did not have 
additional sexually transmitted infections and who were 
treated with each specific antimicrobial drug.
Statistical Analysis
We used the Student t‐test and a test of proportions for sta-
tistical analysis (Statistica 12.0 PL software, https://www.
tibco.com). The level of significance was set at α = 0.05.
Results
N. gonorrhoeae–Positive NAAT Specimens  
and Corresponding Patients
The collection of DNA extracts we examined consisted of 
3,884 N. gonorrhoeae–positive NAAT specimens collect-
ed across South Korea from 2012 through 2017 (Table 1). 
The number of specimens per year varied from 428 in 2012 
to 901 in 2017 (Table 1). Data on the sex and age of pa-
tients were available for 3,422 (88.1%) of specimens. The 
ratio of men to women was 1:0.37, and 71.1% of the speci-
mens were collected from patients in their 20s (43.9%) and 
30s (27.2%).
Molecular Typing of Gonococcal Mosaic penA- 
Positive Specimens
The proportion of mosaic penA alleles in the specimens 
increased annually, from 1.2% (5/428) in 2012 to 23.9% 
(215/901) in 2017 (Table 2). The mosaic penA-10.001, 
previously associated with resistance to ESCs, particu-
larly cefixime and other oral ESCs (4,5,33), was the most 
common mosaic penA allele (n = 572; 94.7% of all mosaic 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 3, March 2019 417
SYNOPSIS
penA-positive specimens). The annual proportion of mo-
saic penA-10.001 among the mosaic penA-positive speci-
mens varied from 60% to 100% (Table 2). Most (76.9%) 
mosaic penA-10.001–positive samples belonged to MLST 
ST1901, but the proportion of sequence type (ST) 1901 
among the mosaic penA-10.001 specimens decreased from 
100% (5/5) in 2012 to 68% (143/210) in 2017. In contrast, 
the proportion of other MLST STs, including ST1588 and 
ST7363, increased. In 2012 and 2013, NG-MAST ST2958 
was the most prevalent ST, but the genetically closely re-
lated NG-MAST ST10668 was most common in 2014 and 
2015. In 2016 and 2017, NG-MAST STs diversified, and 
ST15014 became the most common. 
The mosaic penA-34.001 was found in 1–3 samples 
annually between 2013 and 2017, and the mosaic penA-
72.001 (penA-34.001+P551S) was identified in 10 samples 
between 2013 and 2016. These mosaic penA alleles also 
have been previously associated with ESC resistance inter-
nationally (4,5,31,40). Of particular concern, mosaic penA-
60.001, which has been found in internationally spreading 
ceftriaxone-resistant gonococcal strains since 2015 (12,14–
16,18,19), was identified in a sample in 2017. This sample 
belonged to MLST ST1903 and NG-MAST ST16327 and 
was collected from a man in Seoul (Table 2).
Distribution of Mosaic penA Alleles in  
Different Provinces
We summarized the annual proportions of mosaic penA 
alleles in the 10 different provinces of South Korea from 
2012 through 2017 (Figure 1). In 2012, only 5 mosaic 
penA-positive specimens were identified: 1 each in the 
capital city Seoul (0.5% of the total number of isolates col-
lected in this location), Gyeonggi Province surrounding 
Seoul (1.4%), and North Gyeongsang Province (2.0%) and 
2 (3.1%) in South Gyeongsang Province, which includes 
Busan, the second largest city in South Korea. In 2013, 
the proportions of mosaic penA-positive specimens in 
these 4 provinces increased to 4.1%–7.4%, but no mosaic 
penA-positive specimens were detected in any of the other 
provinces. However, in 2014, while the proportion of mo-
saic penA-positive specimens further increased in these 4 
provinces (to 6.4%–16.5%), mosaic penA-positive speci-
mens also emerged in 4 of the 6 additional provinces (pro-
portions of 7.2%–15.4%). Mosaic penA-positive speci-
mens were widely spread in all provinces of South Korea, 
except Jeju Island, in 2015 (9.7%–34.5%) and 2016 (3.8%–
32.0%). In 2017, the proportion of mosaic penA-positive 
specimens was >20% in all provinces, except South Jeolla 
Province (13.1%), and mosaic penA-positive specimens 
also were found on Jeju Island (33.3%) (Figure 1).
Antimicrobial Drugs Used for Gonorrhea Treatment 
In 2010, 13.1% of gonorrhea patients were treated with 
ceftriaxone, and 17.4% were treated with any ESC, but 
these proportions increased to 30.5% treated with ceftri-
axone and 38.8% treated with ESCs in 2017 (Figure 2). 
With the exception of ceftriaxone, cefixime is the most 
widely used ESC; the proportion of patients treated with 
cefixime increased from 2.9% in 2010 to 6.6% in 2017. In 
2010, 32.8% of patients were treated with spectinomycin 
and 49.6% with fluoroquinolone, but these proportions de-
creased in 2017 to 16.0% treated with spectinomycin and 
26.7% treated with fluoroquinolone (Table 3).
Discussion
The emergence of multidrug-resistant N. gonorrhoeae is 
compromising the treatment of gonorrhea globally. In most 
countries, only ESCs, azithromycin combined with ESCs, 
and spectinomycin remain recommended for the empiric 
treatment of gonorrhea (3–5,8–10,20–23,31,32,41–44).
Among the ESCs, oral cefixime and the more potent 
injectable ceftriaxone have been recommended for the 
treatment of gonorrhea internationally (4,5,10,41–44). 
However, resistance to cefixime emerged in Japan in the 
early 2000s, and cefixime resistance subsequently has been 
reported in many countries globally. Since 2010, resistance 
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Table 1. Number of Neisseria gonorrhoeae–positive nucleic acid amplification test specimens examined, by year and location, South 
Korea, 2012–2017 
Location No. (%) tested specimens  
2012 2013 2014 2015 2016 2017 Total 
Seoul metropolitan area 192 (44.9) 171 (32.6) 185 (30.6) 141 (23.3) 338 (41.2) 252 (28.0) 1,279 (32.9) 
Gyeonggi area, including Incheon 71 (16.6) 96 (18.3) 100 (16.6) 156 (25.7) 191 (23.3) 157 (17.4) 771 (19.9) 
Gangwon  4 (0.9) 12 (2.3) 7 (1.2) 19 (3.1) 16 (1.9) 14 (1.6) 72 (1.9) 
North Chungcheong  6 (1.4) 1 (0.2) 16 (2.6) 19 (3.1) 25 (3.0) 73 (8.1) 140 (3.6) 
South Chungcheong, including 
Daejeon 
22 (5.1) 21 (4.0) 69 (11.4) 62 (10.2) 53 (6.5) 103 (11.4) 330 (8.5) 
North Jeolla  2 (0.5) 2 (0.4) 13 (2.2) 12 (2.0) 24 (2.9) 42 (4.7) 95 (2.4) 
South Jeolla, including Gwanju 17 (4.0) 6 (1.1) 39 (6.5) 43 (7.1) 42 (5.1) 61 (6.8) 208 (5.4) 
North Gyeongsang, including 
Daegu 
49 (11.4) 93 (17.7) 78 (12.9) 93 (15.3) 83 (10.1) 103 (11.4) 499 (12.8) 
South Gyeongsang, including 
Busan and Ulsan 
65 (15.2) 121 (23.1) 97 (16.1) 61 (10.1) 46 (5.6) 93 (10.3) 483 (12.4) 
Jeju  0 1 (0.2) 0 0 3 (0.4) 3 (0.3) 7 (0.2) 
Total 428 (100) 524 (100) 604 (100) 606 (100) 821 (100) 901 (100) 3,884 (100) 
 
 
Cephalosporin-Resistant N. gonorrhoeae
to ceftriaxone, the last remaining option for empiric first-
line monotherapy, also has been described in many coun-
tries (3–19,21,32). The mechanisms of resistance to these 
ESCs are complex and involve different mutations in the 
penA gene, in the promoter or coding region of mtrR, and 
in the porB1b gene. However, the main ESC-resistance 
determinant is evidently the acquisition of a mosaic penA 
allele. The mosaic penA-10.001 was shown to be strongly 
associated with cefixime resistance in gonococcal isolates 
in Japan in the early 2000s (3–5,7,33), which resulted in 
the exclusion of cefixime from the Japanese treatment 
guidelines in 2006 (43). In South Korea, 1 cefixime-resis-
tant isolate cultured in 2004 (2), 1 in 2011, and 3 in 2013 
previously were reported to contain mosaic penA-10.001 
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Table 2. Molecular typing of specimens positive for a Neisseria gonorrhoeae mosaic penA allele by year, South Korea, 2012–2017* 
Year 
No. (%) 
specimens with 
mosaic penA  
Mosaic penA allele 
(no. specimens) 
MLST ST  
(no. specimens) NG-MAST ST (no. specimens) 
2012 5 (1.2) 10.001 (5) 1901 (5) 2958 (5) 
2013 27 (5.2) 10.001 (17) 1901 (21) 2958 (8), 10668 (6), 5682 (1), 6783 (1), 10669 (1) 
72.001 (4) 1407 (3), 436 (1) 
10.001 (1) 7363 (1) 5308 (1) 
10.001 (3) ND (5) ND (3) 
34.001 (2) 10670 (1), ND (1) 
2014 60 (9.9) 10.001 (1) 1588 (1) 6696 (1) 
10.001 (54) 1901 (56) 10668 (33), 2958 (15), 11495 (2), 11493 (1), 11494 (1), 
11496 (1), 11497 (1) 
34.001 (1) 5622 (1) 
72.001 (1) 1407 (1) 
10.001 (3) ND (3) ND (3) 
2015 109 (18.0) 10.001 (2) 1579 (2) 13376 (2) 
10.001 (7) 1588 (7) 12399 (3), 3611 (2), 6696 (1), 10679 (1) 
10.001 (82) 1901 (82) 10668 (38), 2958 (20), 6734 (7), 11495 (4), 1407 (3), 6481 
(3), 4502 (2), 6373 (2), 11497 (1), 13374 (1), 13388 (1), 
13391 (1) 
10.001 (1) 1922 (1) 13393 (1) 
10.001 (10) 7363 (10) 5308 (8), 11562 (1), 13389 (1) 
10.001 (2) 7371 (2) 13390 (1), 13394 (1) 
34.001 (2) 7827 (2) 3702 (2) 
10.001 (2) 8137 (2) 13373 (1), 13392 (1) 
10.001 (1) 10931 (1) 12402 (1) 
2016 185 (22.5) 10.001 (11) 1588 (11) 15024 (7), 15026 (3), 15086 (1) 
10.001 (133) 1901 (148) 15014 (39), 15016 (31), 15015 (28), 7307 (8), 15025 (3), 
15041 (3), 15029 (2), 15045 (2), 11497 (1), 15013 (1), 
15017 (1), 15018 (1), 15019 (1), 15020 (1), 15021 (1), 
15022 (1), 15023 (1), 15027 (1), 15031 (1), 15033 (1), 
15034 (1), 15038 (1), 15042 (1), 15044 (1), 15048 (1) 
27.001 (2) 15015 (2) 
34.001 (3) 4431 (1), 15032 (1), 15039 (1) 
72.001 (10) 15018 (7), 4431 (1), 15016 (1), 15030 (1) 
10.001 (26) 7363 (26) 6910 (13), 15028 (4), 15037 (2), 15046 (2), 15012 (1), 
15040 (1), 15043 (1), 15049 (1), 15050 (1) 
2017 215 (23.9) 10.001 (40) 1588 (40) 15024 (24), 5576 (4), 3611 (3), 15025 (3), 15026 (2), 6696 
(1), 7684 (1), 14668 (1), 16331 (1) 
10.001 (143) 1901 (145) 15014 (33), 15016 (25), 7307 (17), 15015 (16), 5446 (10), 
15032 (3), 16324 (3), 16341 (3), 6734 (2), 15045 (2), 
16270 (2), 16325 (2), 16335 (2), 12402 (1), 13973 (1), 
15018 (1), 15019 (1), 15028 (1), 15029 (1), 16319 (1), 
16320 (1), 16321 (1), 16323 (1), 16328 (1), 16329 (1), 
16332 (1), 16333 (1), 16334 (1), 16336 (1), 16338 (1), 
16342 (1), 16343 (1), 16344 (1), 16346 (1) 
34.001 (2) 15032 (2) 
10.001 (1) 1902 (1) 16339 (1) 
60.001 (1) 1903 (1) 16327 (1) 
10.001 (24) 7363 (25) 6910 (13), 16322 (3), 13044 (1), 13876 (1), 15037 (1), 
15046 (1), 16318 (1), 16337 (1), 16340 (1) 
34.001 (1) 11624 (1) 
10.001 (1) 7371 (1) 16330 (1) 
10.001 (1) 10899 (1) 11895 (1) 
10.001 (1) 11179 (1) 16345 (1) 
*MLST, multilocus sequence typing; ND, not determined (due to insufficient amount of DNA); NG-MAST, N. gonorrhoeae multiantigen sequence typing; 
ST, sequence type. 
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(3). In our study, 1.1% (n = 5) of N. gonorrhoeae–positive 
NAAT specimens contained a mosaic penA allele in 2012. 
This proportion increased significantly in 2017 to 23.9% 
(n = 215; p<0.05). The proportion of mosaic penA-positive 
specimens (n = 209) containing mosaic penA-10.001 was 
100% (n = 5) in 2012 and >90% during all the following 
years, except 2013 (77.8%; 21/27).
Twenty-five (96.2%) of the NAAT specimens con-
taining mosaic penA-10.001 in 2012 and 2013 were col-
lected from the capital region of Seoul and surround-
ing Gyeonggi Province, as well as the Gyeongsang area 
(North and South). Seoul (population 8.8 million; 19.8% 
of the population of South Korea) and the Gyeonggi area 
(29.6% of the population) share 2 large international air-
ports and an international port, which have pivotal roles in 
trading with foreign countries, including China and Japan. 
The South Gyeongsang area (15.6% of the population) in-
cludes Ulsan, Gyeonsangnam-do, and the second largest 
city in South Korea, Busan, which comprises the main 
port in northeast Asia, with close and frequent trading 
routes to Japan. In 2012 and 2013, the proportions of mo-
saic penA-10.001 were 2.2% in the capital area and 4.1% 
in the Gyeongsang area, whereas the proportion was only 
0.8% in the remaining provinces. This indicates that N. 
gonorrhoeae strains with mosaic penA-10.001, associated 
with decreased susceptibility and resistance to ESCs, ini-
tially emerged or were imported to at least 2 areas (Seoul 
and Gyeongsang) of South Korea, possibly from Japan, 
where these strains have been prevalent for many years 
(4,5,7,33). From 2014, the proportion of N. gonorrhoeae 
mosaic penA-10.001 in the other provinces significantly 
increased (from 9.1% in 2014 to 20.9% in 2017; p<0.05); 
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Figure 1. Distribution of specimens positive for a Neisseria gonorrhoeae mosaic penA allele, by year and province, South Korea, 2010–
2017. Numbers shown in each province denote the proportion of samples positive for a mosaic penA allele in 2012. The bar graphs 
describe the percentage of specimens positive for a N. gonorrhoeae mosaic penA allele in each province and year. Seoul is the capital 
city of South Korea, and Gyeonggi Province contains an international airport.
Cephalosporin-Resistant N. gonorrhoeae
accordingly, N. gonorrhoeae strains with mosaic penA-
10.001 spread and diversified, based on NG-MAST STs, 
nationally in South Korea.
Gonococcal resistance to cefixime and other oral ESCs 
is common in South Korea, according to a smaller study (3), 
and the prevalent mosaic penA-10.001 we report causes de-
creased susceptibility and frequently resistance to cefixime 
and other oral ESCs (4,5,7,33). With these facts in mind, oral 
ESCs should be abandoned from the treatment of gonorrhea 
in South Korea. Gonococcal strains with mosaic penA-10.001 
also can cause ceftriaxone treatment failure (17). However, 
mosaic penA-10.001 affects the MICs of ceftriaxone less than 
those of cefixime in general. Thus, ceftriaxone, combined 
with azithromycin, should be the first-line empiric treatment 
in South Korea. However, N. gonorrhoeae specimens con-
taining mosaic penA-34.001 (n = 11) and penA-72.001 (n 
= 15) also were detected. These mosaic penA alleles have 
been associated with ESC resistance globally (4,5,31,40) and 
require only a single additional penicillin binding protein 2 
amino acid alteration (A501P) to develop high-level cef-
triaxone resistance (6,45). Of most concern, mosaic penA-
60.001 was found in a sample collected in Seoul in 2017 
and this mosaic penA allele has been found in internationally 
spreading ceftriaxone-resistant gonococcal strains in Japan, 
Australia, Canada, Denmark, France, the United Kingdom, 
and Ireland since 2015 (12,14–16,18,19,46).
The detailed reasons for the emergence and subse-
quent national spread of gonococcal strains with mosaic 
penA-10.001 in South Korea are not clear. One possibil-
ity is importation of cefixime-resistant gonococcal strains 
containing the mosaic penA-10.001 from Japan, as previ-
ously mentioned. However, increased therapeutic use of 
ESCs, particularly oral ESCs, in South Korea cannot be 
excluded as contributing to the increased spread of ESC-
resistant gonococcal strains. In South Korea, spectinomy-
cin, fluoroquinolones, and ESCs have been used to treat 
gonorrhea since the early 2000s (3). In 2002, most patients 
were treated with spectinomycin; only 8.4% of all patients 
were treated with ceftriaxone, and oral ESCs were rarely 
prescribed. However, 38.8% of patients were treated with 
ESCs (30.5% with ceftriaxone) in 2017. Despite the high 
use of spectinomycin in South Korea for decades, suscep-
tibility to spectinomycin in N. gonorrhoeae has remained 
high. No spectinomycin-resistant gonococcal strain has 
been reported since 1993. Nevertheless, spectinomycin has 
a low eradication rate for pharyngeal gonorrhea (47) and, if 
pharyngeal infection has not been excluded, should be used 
only in dual antimicrobial therapy (e.g., in combination 
with azithromycin). In the 2016 South Korea guideline, 
dual antimicrobial therapy (ceftriaxone 500 mg or 1 g plus 
azithromycin 1 g) is the recommended first-line empiric 
therapy for uncomplicated gonorrhea (48).
The limitations of our study include the unavailability 
of gonococcal isolates, MIC data, rectal or pharyngeal speci-
mens (which are not covered by the national insurance sys-
tem in South Korea), and clinical or epidemiologic informa-
tion regarding patients or treatment outcome. Accordingly, 
phenotypic ESC resistance was not measured; instead mo-
lecular detection of mosaic penA alleles was used to reflect 
the ESC resistance. Nearly all gonococcal strains with ESC 
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Figure 2. Percentages of 
Neisseria gonorrhoeae mosaic 
penA in NAAT specimens and 
gonorrhea patients treated with 
ceftriaxone or any extended-
spectrum cephalosporin, South 
Korea, 2010–2017. Data for 
antimicrobial drug use were 
acquired from the Korea 
Health Insurance Review and 
Assessment Service in South 
Korea. In 2010 and 2011, no 
NAAT samples were available 
for screening of mosaic penA 
alleles. NA, not assessed; NAAT, 
nucleic acid amplification test.
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resistance contain a mosaic penA allele; however, isolates 
with decreased susceptibility or susceptibility to ESCs also 
can contain a mosaic penA allele, and different mosaic penA 
alleles affect the ESC MICs differently (3–8,10–19,24–38). 
Even so, the mosaic penA-10.001 in 94.7% of our mosaic 
penA allele-positive specimens is relatively strongly associ-
ated with resistance to cefixime particularly and other oral 
ESCs, although with a weaker association with ceftriaxone 
resistance. In addition, our molecular approach to identifying 
decreased susceptibility and resistance to ESCs can overes-
timate the ESC resistance. The mosaic penA allele PCR as-
say (34) did not include any internal control for gonococcal 
DNA. However, the assay has been previously evaluated on 
gonococcal strains and detects 1–10 copies of a mosaic penA 
per PCR reaction (34) on urogenital and extragenital gono-
coccal-positive and gonococcal-negative NAAT samples 
(49,50). Finally, the distribution of specimens could not be 
allocated by population in an ideal way and the suboptimal 
number of samples, especially from the Gyeonggi area, Jeju, 
Gangwon, South Gyeongsang, South Jeolla, and North Je-
olla provinces in some years, might have underestimated the 
prevalence of N. gonorrhoeae specimens with mosaic penA 
allele in these provinces.
In conclusion, we describe the initial emergence and 
subsequent national spread of N. gonorrhoeae strains 
with mosaic penA alleles (penA-10.001 in 94.7% of speci-
mens), associated with decreased susceptibility and re-
sistance to ESCs, in NAAT specimens collected across 
South Korea from 2012 through 2017. The proportion of 
penA-10.001, frequently causing resistance to cefixime 
and other oral ESCs, increased during these years. Only 
a few additional mutations in penA-10.001 are required 
for development of high-level resistance to ceftriaxone. 
Furthermore, we identified mosaic penA-34.001 and 
penA-60.001, both associated with multidrug-resistant 
gonorrhea and international spread of cefixime and ceftri-
axone resistance (4,5,12,14–16,18,19,31,40). The mosaic 
penA-60.001 has been found in internationally spreading 
ceftriaxone-resistant gonococcal strains in Japan, Austra-
lia, Canada, Denmark, the United Kingdom, France, and 
Ireland since 2015 (12,14–16,18,19,46). Nevertheless, N. 
gonorrhoeae strains with ESC resistance due to nonmo-
saic penA alleles, such as penA-13.001, also are spreading 
in South Korea (3). Consequently, it is essential to estab-
lish a systematic, regular, and quality-assured phenotypic 
AMR surveillance system for N. gonorrhoeae in South 
Korea. Implementing the use of molecular methods for 
prediction of AMR or antimicrobial susceptibility is also 
crucial. These molecular methods will effectively sup-
port phenotypic AMR surveillance and enable large-scale 
screening of N. gonorrhoeae–positive NAAT specimens, 
which represent most of N. gonorrhoeae diagnostic speci-
mens in many countries internationally.
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